Varivax Related Published Studies
Well-designed clinical trials related to Varivax (Varicella Vaccine)
Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. [2011.05.17]
Effectiveness of 2 doses of varicella vaccine in children. [2011.02.01]
Varicella-related hospitalizations in the United States, 2000-2006: the 1-dose varicella vaccination era. [2011.02]
Association between varicella zoster virus infection and atopic dermatitis in early and late childhood: a case-control study. [2010.08]
Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. [2010.08]
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. [2010.06]
Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. [2010.04]
Safety of a refrigerator-stable varicella vaccine (VARIVAX) in healthy 12- to 15-month-old children: A randomized, double-blind, cross-over study. [2009.07]
[Study on epidemiological effect of the freeze-dried attenuated live varicella vaccine] [2009.06]
[Study on epidemiological effect of the freeze-dried attenuated live varicella vaccine]. [2009.06]
Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. [2009.05.05]
Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. [2009.04.14]
Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. [2009.01.14]
Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. [2008.08]
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. [2008.03.15]
Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. [2008.03]
Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. [2007.10]
Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. [2007.08]
Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). [2007.06]
Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi. [2007.04]
A role for genetics in the immune response to the varicella vaccine. [2007.04]
Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. [2007.03.01]
Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age. [2006.11.17]
Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. [2006.10]
The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. [2006.07]
Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. [2006.04]
Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. [2006.04]
A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. [2006.02]
Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. [2005.08]
Efficacy of postexposure immunization with live attenuated varicella vaccine in the household setting--a pilot study. [2004.12.02]
Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults. [2004.09]
Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old. [2004.03]
Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity. [2004.03]
Ten year follow-up of healthy children who received one or two injections of varicella vaccine. [2004.02]
Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months. [2003.09]
Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. [2002.12.13]
A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. [2002.07.26]
Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. [2002.07.04]
Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. [2002.06]
Risk factors for breakthrough varicella in healthy children. [1998.12]
A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. [1998.11]
Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. [1998.11]
Evaluation of a live attenuated varicella vaccine in 15- to 18-month-old healthy children. [1998.01]
Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. [1997.09]
Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group. [1997.07]
Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. [1997.05]
Dose titration study of live attenuated varicella vaccine in healthy children. Pennridge Pediatric Associates. [1997.02]
Efficacy of high-titer live attenuated varicella vaccine in healthy young children. [1996.11]
Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. [1996.11]
Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. [1996.08]
Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. [1996.03]
Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. [1996.01]
Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months. [1995.12]
Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. [1995.08]
Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. [1995.02]
Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. [1995.01]
Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. [1994.10]
The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine. [1993.12]
Immune response of elderly individuals to a live attenuated varicella vaccine. [1992.08]
Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. [1992.05]
Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. [1992.03]
Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy. [1991.12]
Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. [1991.11]
Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. [1991.09]
Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. [1991.09]
The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. [1990.11]
Combined vaccine against measles, mumps, rubella, and varicella. [1988.06]
Well-designed clinical trials possibly related to Varivax (Varicella Vaccine)
Probiotics and the immunological response to infant vaccinations: a prospective, placebo controlled pilot study. [2011.04]
Vaccines for prophylaxis of viral infections in patients with hematological malignancies. [2011.03.16]
Concomitant administration of zoster and pneumococcal vaccines in adults >/=60 years old. [2010.11]
Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. [2010.09]
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. [2010.06.07]
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. [2010.05.04]
Vaccination: a new option to reduce the burden of herpes zoster. [2010.03]
Effect of a zoster vaccine on herpes zoster-related interference with functional
status and health-related quality-of-life measures in older adults. [2010]
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a
history of herpes zoster. [2010]
Vaccination: a new option to reduce the burden of herpes zoster. [2010]
Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. [2009.06]
Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. [2009.05]
A novel vaccine (Zostavax) to prevent herpes zoster. [2008.04]
Vaccination against Herpes Zoster and Postherpetic Neuralgia. [2008.03.01]
A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. [2008.02]
Vaccination to prevent herpes zoster in older adults. [2008.01]
Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia. [2007.12]
Safety and Immunogenicity Profile of the Concomitant Administration of ZOSTAVAX and Inactivated Influenza Vaccine in Adults Aged 50 and Older. [2007.10]
Safety and tolerability of a high-potency zoster vaccine in adults > or years of age. [2007.02.26]
[Geriatrics] [2007.01.10]
Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. [2006.10]
A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia. [2006.10]
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. [2005.06.02]
Other research related to Varivax (Varicella Vaccine)
[Post-exposure varicella prophylaxis]. [2011.09.06]
Near elimination of varicella deaths in the US after implementation of the vaccination program. [2011.08]
Second-dose varicella vaccination coverage in children and adolescents in a managed care organization in California, 2006-2009. [2011.08]
Influenza and pneumococcal vaccination and varicella status in inflammatory arthritis patients. [2011.07]
Clinical Inquiry: is it safe to vaccinate children against varicella while they're in close contact with a pregnant woman? [2011.07]
Varicella rates among unvaccinated and one-dose vaccinated healthy children in Izmir, Turkey. [2011.07]
Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization. [2011.06.01]
Preventing varicella in children with malignancies: what is the evidence? [2011.06]
Immune response of varicella vaccinees to different varicella-zoster virus genotypes. [2011.05.17]
An outbreak of varicella among schoolchildren in Taipei. [2011.04.12]
Vaccine-related varicella-zoster rash in a hospitalized immunocompetent patient. [2011.04]
|
